Enmodulin, Inc.
Records under this name other than the patents Enmodulin, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 6 of 6 · Back to Enmodulin, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,536,135 | Adaptive biochemical signatures Lapsed on the fee record Ended Sep 17, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 17, 2025 | From the USPTO record |
| US 7,371,813 | Method for Use of Igf-Binding Protein for Selective Sensitization of Target Cells in Vivo Term ended Ended no later than Nov 1, 2022 · Low confidence | Term ended | Ended no later than Nov 1, 2022 | Low confidence |
| US 6,914,049 | IGF-binding protein-derived peptide or small molecule Term ended Term ended Oct 21, 2022 · From the USPTO record | Term ended | Term ended Oct 21, 2022 | From the USPTO record |
| US 6,861,406 | IGF-binding protein-derived peptide Term ended Term ended Aug 9, 2022 · From the USPTO record | Term ended | Term ended Aug 9, 2022 | From the USPTO record |
| US 7,611,893 | Metal-binding therapeutic peptides Lapsed on the fee record Ended Nov 3, 2017 · From the USPTO record | Lapsed on the fee record | Ended Nov 3, 2017 | From the USPTO record |
| US 6,887,851 | IGF-binding protein-derived peptide Lapsed on the fee record Ended May 3, 2017 · From the USPTO record | Lapsed on the fee record | Ended May 3, 2017 | From the USPTO record |